DBV rises as FDA filing marks key milestone for kids' peanut patch

By Reuters News

** DBV Technologies DBV.PA shares rise 3.4% after the French biotech submitted a biologics license application (BLA) to the FDA for its Viaskin Peanut patch for children aged four to seven

** The submission marks an "important milestone" for DBV, Portzamparc says, following an earlier unsuccessful application for the 4–11 age group in 2020

** The broker says the clinical data are stronger this time; the latest study met its statistical significance criterion, unlike the first attempt

** DBV has also redesigned the patch to make it less likely to fall off accidentally, which should help reassure regulators, Portzamparc says

** The treatment for peanut allergy has received breakthrough therapy designation, and DBV has now requested priority review

** If the FDA approves the patch, Portzamparc says DBV could begin generating revenue in the US from children aged 4 to 7 in 2027

** Up to the previous session's close, shares were down 40.3%​ year-to-date

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.